Spotlight on rituximab as a new therapeutic option for dermatomyositis and thrombotic thrombocytopenic purpura.
This month's Spotlight on... will focus on rituximab, a chimeric monoclonal antibody approved for the treatment of non-Hodgkin's lymphoma, but it has been revealed as a promising therapeutic approach for two serious conditions: dermatomyositis and refractory thrombotic thrombocytopenic purpura.
Ferrer
E
E
Prous Science Medical Information Department, Barcelona, Spain. journals@prous.com
Moral
Maria Angels
MA
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D002986:Clinical Trials as Topic; D003882:Dermatomyositis / Q000188:drug therapy*; D006801:Humans; D007155:Immunologic Factors / Q000627:therapeutic use*; D011697:Purpura, Thrombotic Thrombocytopenic / Q000188:drug therapy*; D000069283:Rituximab
D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D007155:Immunologic Factors; D000069283:Rituximab